YU45102A - Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje - Google Patents

Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje

Info

Publication number
YU45102A
YU45102A YU45102A YUP45102A YU45102A YU 45102 A YU45102 A YU 45102A YU 45102 A YU45102 A YU 45102A YU P45102 A YUP45102 A YU P45102A YU 45102 A YU45102 A YU 45102A
Authority
YU
Yugoslavia
Prior art keywords
leflunomide
making
crystalline form
new crystalline
novel processes
Prior art date
Application number
YU45102A
Other languages
English (en)
Inventor
Ilya Avturov
Neomi Gershon
Judith Aronhime
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of YU45102A publication Critical patent/YU45102A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Opisan je novi Oblik III leflunomida, kao i postupak njegovog dobijanja. Predmetni pronalazak takođe obezbeđuje ekonomični postupak dobijanja Oblika II leflunomida i postupak dobijanja Oblika I iz Oblika III leflunomida. Takođe su opisani i farmaceutski preparati, oblici za doziranje koji sadrže novi oblik i postupci njihove primene u lečenju reumatoidnog artritisa.[New leflunomide Form III is disclosed, along with processes for preparing it. The present invention also provides an economic process for preparing leflunomide Form II and a process for preparing leflunomide Form I from leflunomide Form III. Pharmaceutical compositions and dosage forms containing the new form and methods of using them for the treatment of rheumatoid arthritis are also disclosed.
YU45102A 1999-12-16 2000-12-14 Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje YU45102A (sh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17123799P 1999-12-16 1999-12-16
US17122899P 1999-12-16 1999-12-16
US18264700P 2000-02-15 2000-02-15
US20241600P 2000-05-08 2000-05-08

Publications (1)

Publication Number Publication Date
YU45102A true YU45102A (sh) 2006-01-16

Family

ID=27496942

Family Applications (1)

Application Number Title Priority Date Filing Date
YU45102A YU45102A (sh) 1999-12-16 2000-12-14 Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje

Country Status (15)

Country Link
US (3) US6610718B2 (sh)
EP (1) EP1242077A4 (sh)
JP (1) JP2003517011A (sh)
KR (1) KR20020067545A (sh)
CN (1) CN1411373A (sh)
AU (1) AU779931B2 (sh)
CA (1) CA2397601A1 (sh)
CZ (1) CZ20022000A3 (sh)
HR (2) HRP20020521A2 (sh)
HU (1) HUP0204069A3 (sh)
IL (1) IL149792A0 (sh)
PL (1) PL356243A1 (sh)
SK (1) SK8332002A3 (sh)
WO (1) WO2001043742A1 (sh)
YU (1) YU45102A (sh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
KR20020067545A (ko) * 1999-12-16 2002-08-22 테바 파마슈티컬 인더스트리즈 리미티드 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형
US20030153585A1 (en) * 2000-01-13 2003-08-14 Sven-Alexander Schreder Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
PL366088A1 (en) * 2000-02-15 2005-01-24 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
WO2006103506A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Sertraline-containing pharmaceutical compositions and a process for preparation thereof
CN101563082A (zh) * 2006-09-05 2009-10-21 窦德献 治疗免疫介导性皮肤病的组合物和方法
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
AU2008315757A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
CN102272108A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 用于分析波生坦及相关物质的hplc方法以及这些物质作为参比标准和标记的用途
CN101817797B (zh) * 2009-02-26 2013-04-10 江苏亚邦爱普森药业有限公司 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
US11801232B2 (en) * 2019-11-27 2023-10-31 Yale University Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
GB8619432D0 (en) * 1986-08-08 1986-09-17 Lilly Industries Ltd Pharmaceutical compounds
HU222234B1 (hu) * 1990-05-18 2003-05-28 Aventis Pharma Deutschland Gmbh. Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19610955A1 (de) * 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
EP0933633A1 (en) * 1997-12-11 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Process for obtaining L-dihydroorotic acid and use thereof
US7691890B2 (en) * 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1196414B1 (en) * 1999-06-25 2003-09-03 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
KR20020067545A (ko) * 1999-12-16 2002-08-22 테바 파마슈티컬 인더스트리즈 리미티드 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형
PL366088A1 (en) * 2000-02-15 2005-01-24 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US6548527B2 (en) * 2000-03-27 2003-04-15 The General Hospital Corporation Treatments for immune-mediated ear disorders
WO2002013822A1 (en) * 2000-08-14 2002-02-21 Teva Pharmaceutical Industries Ltd. Micronized leflunomide
PT1401801E (pt) * 2000-08-24 2007-02-28 Univ Tennessee Res Foundation Modulares selectivos de receptor de androgénio e métodos para a sua utilização
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050064038A1 (en) * 2003-08-13 2005-03-24 Dinh Thomas Q. Active agent delivery systems including a single layer of a miscible polymer blend, medical devices, and methods
EP1684820A2 (en) * 2003-08-13 2006-08-02 Medtronic, Inc. Active agent delivery systems including a miscible polymer blend, medical devices, and methods
US20050053600A1 (en) * 2003-09-09 2005-03-10 Lane Thomas E. Methods for treating rheumatoid arthritis

Also Published As

Publication number Publication date
CN1411373A (zh) 2003-04-16
KR20020067545A (ko) 2002-08-22
CA2397601A1 (en) 2001-06-21
CZ20022000A3 (cs) 2003-02-12
HUP0204069A3 (en) 2005-01-28
US6806373B2 (en) 2004-10-19
US20010031878A1 (en) 2001-10-18
US20030203952A1 (en) 2003-10-30
EP1242077A4 (en) 2006-01-04
AU779931B2 (en) 2005-02-17
PL356243A1 (en) 2004-06-28
US20050004191A1 (en) 2005-01-06
HRP20020521A2 (en) 2004-08-31
JP2003517011A (ja) 2003-05-20
HUP0204069A2 (hu) 2003-04-28
US6610718B2 (en) 2003-08-26
EP1242077A1 (en) 2002-09-25
SK8332002A3 (en) 2003-04-01
HRP20050176A2 (en) 2005-08-31
IL149792A0 (en) 2002-11-10
WO2001043742A1 (en) 2001-06-21
AU2578801A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
YU45102A (sh) Novi kristalni oblik leflunomida i novi postupci za njegovo dobijanje
PL345215A1 (en) Novel form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same
HK1067120A1 (en) Glutaminyl based dpiv inhibitors
PL337126A1 (en) Novel compounds
PL340836A1 (en) Novel compounds
GR3030342T3 (en) Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase.
MX9805253A (es) Antagonistas del receptor de vitronectina.
MY122189A (en) Farnesyl protein transferase inhibitors for treating arthropathies
MXPA02012795A (es) Carvedilol.
HU9300685D0 (en) Method for producing crystallic momethazone-furoate-monohydrate and pharmaceutical preparatives containing it
BG105009A (en) Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline
GB0016040D0 (en) Novel process for preparing crystalline particles
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
GB0015981D0 (en) Novel process for preparing crystalline particles
HU9601113D0 (en) Delta16 unsaturated c17 heterocyclic steroids useful as steroid c17-20 lyase inhibitors, pharmaceutical compositions containing them and process for their production
ES8704482A1 (es) Procedimiento para la preparacion de silibinina extenta de isosilibina
HRP20010969B1 (en) Novel piperazinylalkylthiopyrimidine derivatives,
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
TNSN00249A1 (en) Stabilization of wine
UA66792C2 (uk) Спосіб отримання 2-арил-3-арил-5-галогенпіридинів, що використовуються як інгібітори сох-2 (варіанти)
IL146811A0 (en) Novel method for preparing benzoperhydroisoindole compounds
GB9909229D0 (en) Enantiomers of mercapto lactones and processes for their synthesis
BG108151A (en) Caloporoside derivatives, methods for the production thereof and their use
UA66859C2 (uk) Спосіб стереохімічно контрольованого одержання ізомерно чистих високозаміщених азациклічних сполук
MY111508A (en) Process for the production of c-substituted diethylenetriamines